the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock

Spinal Shock Clinical Trial

Official title:

The Effect of Oral Midodrine Versus Oral Desmopressin Acetate Use for Liberation From IV Noradrenaline in Intensive Care Unit Patients Recovering From Spinal Shock .

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04586790
• Other study ID #: oral vasopressors
• Status: Recruiting
• Phase: Phase 2
• Start date: October 15, 2020
• Est. completion date: January 28, 2021

Study information

• Verified date: October 2020
• Source: Assiut University
• Contact: Ahmed T Ahmed, lecture
• Phone: 01062716629
• Email: Ahmedtalaat_ahmed[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

the study is developed to evaluate the effect of use of oral vasopressors (midodrine versus minirin) on weaning ICU patients from IV vasopressors (noradrenaline) and compare between them for efficacy in shortage the duration of IV vasopressor and has low complications and side effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: January 28, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age of 18 - 60 years.

• Patients of both genders.

• Patients diagnosed by spinal shock and they are in the recovery stage .

Exclusion Criteria:

• Patient refusal.

• Anuric or oliguric patients or patients with chronic kidney disease.

• Patients with allergy to medication included in the study.

Related Conditions & MeSH terms

• Shock
• Spinal Shock

Intervention

Drug:
• Midodrine Oral Tablet
midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
• Minirin oral tablet
Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
• Nor-Adrenaline
control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .

Locations

Country	Name	City	State
Egypt	Ahmed Talaat Ahmed	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Ahmed talaat ahmed aly

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	liberation the patient from IV vasopressors with maintaining hemodynamics.	Blood pressure will be assessed regularly every 15 minutes	48 hrs